Endothelial dysfunction in heart failure identifies responders to cardiac resynchronization therapy

Heart Rhythm

Volumn 5, Issue 9, 2008, Pages 1229-1235

  Akar, Joseph G ^a   Al Chekakie, M Obadah ^a   Fugate, Tyler ^b   Moran, Lynn ^b   Froloshki, Borislav ^b   Varma, Niraj ^a   Santucci, Peter ^a   Wilber, David J ^a   Matsumura, Martin E ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Division of Cardiology   (United States)

Author keywords

Biventricular pacing; Cardiac resynchronization therapy; Endothelial dysfunction; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; METFORMIN; NITRATE; SULFONYLUREA;

ADULT; AGED; ARTICLE; BRACHIAL ARTERY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; FEMALE; FUNCTIONAL STATUS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QRS COMPLEX; QUALITY OF LIFE; TREATMENT RESPONSE; VASODILATATION; WALKING;

AGED; CARDIAC PACING, ARTIFICIAL; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 50949133170     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2008.05.027     Document Type: Article

References (24)

1. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
2. Yeboah J., Crouse J.R., Hsu F.C., et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 115 (2007) 2390-2397
3. Perticone F., Ceravolo R., Pujia A., et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104 (2001) 191-196
4. Targonski P.V., Bonetti P.O., Pumper G.M., et al. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 107 (2003) 2805-2809
5. Gokce N., Keaney Jr. J.F., Hunter L.M., et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41 (2003) 1769-1775
6. Katz S.D., Hryniewicz K., Hriljac I., et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111 (2005) 310-314
7. Meyer B., Mortl D., Strecker K., et al. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol 46 (2005) 1011-1018
8. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
9. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
10. Bax J.J., Abraham T., Barold S.S., et al. Cardiac resynchronization therapy: part 1-issues before device implantation. J Am Coll Cardiol 46 (2005) 2153-2167
11. Freimark D., Feinberg M.S., Matezky S., et al. Impact of short-term intermittent intravenous dobutamine therapy on endothelial function in patients with severe chronic heart failure. Am Heart J 148 (2004) 878-882
12. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
13. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 7 (2001) 176-182
14. Yu C.M., Abraham W.T., Bax J., et al. Predictors of response to cardiac resynchronization therapy (PROSPECT)-study design. Am Heart J 149 (2005) 600-605
15. Linde C., Gold M., Abraham W.T., et al. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure-the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Am Heart J 151 (2006) 288-294
16. Young J.B., Abraham W.T., Smith A.L., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 289 (2003) 2685-2694
17. Rector T.S., and Cohn J.N. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 124 (1992) 1017-1025
18. Beshai J.F., Grimm R.A., Nagueh S.F., et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 357 (2007) 2461-2471
19. Bleeker G.B., Bax J.J., Fung J.W., et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol 97 (2006) 260-263
20. Borlaug B.A., Melenovsky V., Russell S.D., et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114 (2006) 2138-2147
21. Meredith I.T., Currie K.E., Anderson T.J., et al. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol 270 (1996) H1435-H1440
22. Joannides R., Haefeli W.E., Linder L., et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91 (1995) 1314-1319
23. Cooke J.P., Rossitch Jr. E., Andon N.A., et al. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest 88 (1991) 1663-1671
24. Pohl U., Holtz J., Busse R., et al. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 8 (1986) 37-44